CDC Recommends New RSV Shot to Protect Babies from Illness

The Centers for Disease Control and Prevention (CDC) has recommended an injectable RSV drug, Beyfortus, for all babies under 8 months old and some older infants to protect against respiratory syncytial virus (RSV) ahead of the anticipated fall spread. The drug, which acts similarly to a vaccine by delivering antibodies directly to the bloodstream, is intended for babies born during or entering their first RSV season and infants at increased risk of severe RSV disease. Last year's RSV season led to a spike in severe illness, overwhelming children's hospitals. Beyfortus, approved by the FDA last month, is expected to be available in the U.S. before the 2023-2024 RSV season. The shot will be covered under the CDC's Vaccines for Children Program.